COMMUNIQUÉS West-GlobeNewswire

Amphera Recruits First Patients to Pivotal Phase II/III study of MesoPher to Treat Pleural Mesothelioma
18/03/2019
Proprietary immuno-oncology approach harnesses autologous dendritic cell therapy to treat an orphan-designated cancer `s-Hertogenbosch, The Netherlands, March 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amphera B.V [...]
DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
18/03/2019
MINNEAPOLIS, March 18, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March 19th. DiaMedica’s [...]
Virbac: 2018 operating profit from ordinary activities grew by 13.4%
18/03/2019
Virbac: 2018 operating profit from ordinary activities grew by 13.4% CONSOLIDATED DATA AS OF DECEMBER 31 st in € million 2018 2017 % change 2018/2017 Revenue from ordinary activities 868.9 861.9 +0.8 % Evolution at [...]
Virbac : résultat opérationnel courant 2018 en croissance de +13,4%
18/03/2019
Virbac : résultat opérationnel courant 2018 en croissance de +13,4% CHIFFRES CONSOLIDÉS AU 31 DÉCEMBRE en millions € 2018 2017 Évolution 2018/2017 Chiffre d’affaires 868,9 861,9 +0,8 % Évolution à taux de change [...]
Ossur Hf : Transactions in relation to share buyback program
18/03/2019
Announcement no. 19/2019 18 March 2019 Transactions in relation to share buyback program On 9 October 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2018. The purpose of the share [...]
Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher
18/03/2019
Resverlogix also advances its Fabry Disease indication data and planning CALGARY, Alberta, March 18, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the advancement [...]
BioPorto A/S - Annual General Meeting
18/03/2019
March 18, 2019 Announcement no. 4 BioPorto A/S - Annual General Meeting Today, BioPorto A/S held its Annual General Meeting where the shareholders took note of the report on the Company’s activities and adopted the 2018 [...]
HPV Vaccine Mandate Ill-Advised, States Association of American Physicians and Surgeons (AAPS)
18/03/2019
TUCSON, Ariz., March 18, 2019 (GLOBE NEWSWIRE) -- Connecticut is considering legislation to end the religious exemption for mandated vaccines and to mandate human papillomavirus (HPV) vaccines for pre-teens, reports the [...]
Oasmia announces a prospectus regarding admission to trading of new shares
18/03/2019
Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) has prepared a prospectus regarding the admission to trading of the 22,948,535 shares in the Company that were issued in the directed issue which was announced [...]
BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
18/03/2019
MORRISTOWN, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) as adjunctive therapy [...]
Novo Nordisk A/S - Share repurchase programme
18/03/2019
Bagsværd, Denmark, 18 March 2019 - On 1 February 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 [...]
Coherus BioSciences Receives Transitional Pass-Through Status from CMS
18/03/2019
REDWOOD CITY, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that the Centers for Medicare and Medicaid Services (CMS) approved UDENYCA™ (pegfilgrastim-cbqv) [...]
Coherus BioSciences Appoints Thomas Fitzpatrick Chief Legal Officer
18/03/2019
REDWOOD CITY, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Thomas Fitzpatrick as its Chief Legal Officer. Mr. Fitzpatrick brings more than 20 years [...]
Eidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACC) and Presentation at American College of Cardiology (ACC) Scientific Sessions
18/03/2019
AG10 demonstrated equivalent, near-complete stabilization of TTR in wild-type and mutant subjects with TTR amyloid cardiomyopathy (ATTR-CM). AG10 treatment normalized serum TTR levels, a prognostic indicator of survival [...]
XACT Robotics expands its patents portfolio to include the use of ultrasound
18/03/2019
CAESAREA, Israel, March 18, 2019 (GLOBE NEWSWIRE) -- XACT Robotics Ltd. today announced that the European Patent Office (EPO) will grant a patent expanding the Company’s patent portfolio to include the use of its [...]
Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
18/03/2019
Pfizer / Zenith TNBC program collaboration on target to dose first patient in April 2019 Phase 2 mCRPC program and clinical data to be presented at AACR CALGARY, Alberta, March 18, 2019 (GLOBE NEWSWIRE) -- Zenith [...]
Adverum Biotechnologies to Participate in Upcoming Conferences
18/03/2019
MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the [...]
Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update
18/03/2019
Achieves Record Annual IXINITY ® Net Revenue of $23.1 Million Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic [...]
Innovate Biopharmaceuticals Announces Entry Into Securities Purchase Agreement to Fund Initiation of the First Phase 3 Celiac Disease Clinical Trial
18/03/2019
RALEIGH, N.C., March 18, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate” or the “Company”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and [...]

Pages